TickerFacts.

DBV Technologies S.A. (DBVT): Operating Income

Annual figures by period end, from SEC filings.

-$147.06M
Year ended 2025-12-31
2019-12-31: -$171.02M2020-12-31: -$158.84M2021-12-31: -$98.61M2022-12-31: -$96.63M2023-12-31: -$76.43M2024-12-31: -$116.59M2025-12-31: -$147.06M-$147.06M
2019-12-31 Operating Income (USD) 2025-12-31
Period endedOperating IncomeChange YoYSource filing
2025-12-31-$147.06Mn/m2026-03-26, From 2025-01-01
2024-12-31-$116.59Mn/m2026-03-26, From 2024-01-01
2023-12-31-$76.43Mn/m2025-04-11, From 2023-01-01
2022-12-31-$96.63Mn/m2024-03-07, From 2022-01-01
2021-12-31-$98.61Mn/m2023-03-02, From 2021-01-01
2020-12-31-$158.84Mn/m2022-03-09, From 2020-01-01
2019-12-31-$171.02Mn/a2021-03-17, From 2019-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating IncomeChange YoY
DBV Technologies S.A. (DBVT)2025-12-31-$147.06Mn/m
Zeo ScientifiX, Inc. (ZEOX)2025-10-31-$5.39Mn/m
Fate Therapeutics Inc (FATE)2025-12-31-$147.70Mn/m
Prime Medicine, Inc. (PRME)2025-12-31-$208.35Mn/m
Ocugen, Inc. (OCGN)2025-12-31-$62.92Mn/m
CG Oncology, Inc. (CGON)2025-12-31-$190.77Mn/m
CRISPR Therapeutics AG (CRSP)2025-12-31-$664.57Mn/m
Surrozen, Inc. (SRZN)2025-12-31-$42.09Mn/m
Curis Inc (CRIS)2025-12-31-$5.71Mn/m

Compare DBVT, ZEOX, FATE, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗